LifeSCI Capital initie la couverture de la société Genkyotex

information fournie par Boursorama •02/06/2017 à 08:00

Genkyotex (Euronext Paris: GKTX.PA) is a clinical stage biotechnology company focused on the development of anti-NADPH oxidase (NOX) enzyme therapies. The Company
is developing lead asset GKT831, an inhibitor of NOX 1 and 4, for the treatment of primary biliary cholangitis (PBC) and potentially other fibrotic conditions. Genkyotex is also
developing GKT771, a selective NOX 1 inhibitor, and plans to evaluate this compound for patients with inflammatory pain or possibly other related indications. Genkyotex expects to
initiate a Phase II study with GKT831 for PBC in the second quarter of 2017, and interim results are anticipated in the first half of 2018. The Company also plans to launch a Phase I
pharmacodynamics study with GKT771, which is set to begin in the second half of 2017.